Amniotic membrane extract eye drops for ocular surface diseases: use and clinical outcome in real-world practice
Amniotic membrane extract eye drops for ocular surface diseases: use and clinical outcome in real-world practice
复制标题
羊膜提取物滴眼液治疗眼表疾病：现实世界实践中的使用和临床结果
DOI：
10.1007/s10792-021-01856-4
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Pablo Infiesta Madurga
中科院分区：
文献类型：
--
作者：
N. Sabater;M. Figueras;Miriam Ferrán;E. Agustí;E. Martínez;M. Pérez;A. Vilarrodona;R. Casaroli;Diana Carlos Luis Mónica Oscar Miriam Sara Laia Maite Ra Mora Ramírez Moser Lecumberri López Gris Castellón;D. Mora Ramírez;C. L. Moser;M. Lecumberri López;Oscar Gris Castellón;Miriam Barbany Rodríguez;S. Martín Nalda;Laia Bisbe López;M. Sainz de la Maza;R. Quintana;Josep Torras Sanvicens;N. Planas;R. Iturralde;Miquel Domingo Vinyals;Jeisibel Malave;Jorge Pradas Chacón;Suhel Elnayef;D. Ortiz;Silvia Bover;N. Barnils;Pablo Infiesta Madurga
目的研究羊膜提取物滴眼液（AMEED）用于眼表疾病（OSD.MethodsA回顾性研究2018年1月至2020年1月期间接受局部AMEED治疗的患者的适应症和临床结局。根据特定的OSD-干眼病（DED）和伤口愈合延迟（WHD）组，将患者分为两组。人口统计学，合并症，治疗持续时间和临床outcomes进行了analysed.ResultsA共50眼的36例患者有或没有以前的治疗。与WHD组相比，DED组的患者出现更多的全身性合并症（83 vs 22%;p< 0.001），并且在AMEED治疗下花费的平均时间（10 vs 7.2个月平均值）更多（p= 0.0104）。4例患者报告了长期治疗（超过24个月）。两组报告了总体相似的症状改善（DED 88.9% vs WHD 100%;p= 0.486），WHD组尤其包括一般缓解（78%），DED组报告了更多的疼痛改善（44%）（p= 0.011）。对于既往接受自体血清治疗的患者，主观或客观改善均无统计学差异。总的成功率为94.4%的情况下，没有发现不良事件。结论AMEED管理是一个有前途的手段来治疗OSD，如干眼，持续性上皮缺损和角膜溃疡。尽管AMEED可能有效治疗重度DED和持续性上皮缺损或角膜溃疡，但由于缺乏对照临床试验，结论有限。
PurposeTo study the indications and clinical outcomes, in a real-word setting, of amniotic membrane extract eye drops (AMEED) use for ocular surface disease (OSD).MethodsA retrospective study of patients treated with topical AMEED between January 2018 and January 2020 was conducted. Patients were classified in two groups according to specific OSD—dry eye disease (DED) and wound healing delay (WHD) groups. Demographics, comorbidities, treatment duration and clinical outcomes were analysed.ResultsA total of 50 eyes of 36 patients with or without previous treatments were included. Patients in the DED group presented more systemic comorbidities (83 vs 22%;p< 0.001) and spent more mean time under AMEED treatment (10 vs 7.2 months average) than the WHD group (p= 0.0104). In four patients, long-term treatment (more than 24 months) was reported. Global similar symptomatic improvement was reported for both groups (DED 88.9% vs WHD 100%;p= 0.486), with the WHD group especially consisting in general relief (78%) and the DED group reporting more pain improvement (44%) (p= 0.011). Regarding patients with autologous serum as a previous treatment, no statistical differences were found in subjective or objective improvement. An overall success was achieved in 94.4% of the cases and no adverse events were found.ConclusionAMEED administration is a promising mean to treat OSD such as dry eye, persistent epithelial defect and corneal ulcers. Although AMEED may be effective in the treatment of severe DED and persistent epithelial defect or corneal ulcers, conclusions are limited owing to the absence of controlled clinical trials.